Why is HEB accusing its former CFO of defamation?
"On February 7, 2014, Charles T. Bernhardt III (“Bernhardt”) filed a Complaint in the Philadelphia Court of Common Pleas asserting that under an employment agreement dated December 6, 2011, the Company currently owes Bernhardt certain wages, fringe benefits and severance payments by reason of his resignation from employment as Chief Financial Officer from the Company. The claims against the Company included breach of contract, violation of the Pennsylvania Wage Protection Collection Law (“WPCL”) and anticipatory breach of the employment agreement. ...On July 23, 2014, the Company answered and asserted its defenses to the Second Amended Complaint, and also asserted counterclaims against Bernhardt on behalf of the Company and the individual defendants named in the Complaint. These counterclaims included claims against Bernhardt for breach of contract, corporate defamation/false light and defamation. In addition, the Company has asserted a claim for the return of corporate property which Bernhardt is believed to have taken at the time of his departure. Discovery in the matter is ongoing."
The most current (3rd quarter 10Q) reports that:
"Shares sold at the market 24,894,781"
The 2nd quarter 10Q reported:
"Shares sold at the market 20,685,021"
So, over a period of three months, that is an increase of 4,209,760 shares that were dumped at the market. So they are dumping shares at a rate of 1,403,253 per month.
Patient testimonials are meaningless as scientific evidence.
From their 8K regarding the recent meeting:
"Annual, non-binding advisory resolution, by stockholders on the elements of Executive Compensation:
For: 8,754,513 Against: 10,119,874 Abstain: 807,219 "
At the stage in which humans become symptomatic for ebola, it is probably too late for interferon administration to help.
Also, poly I : C is already in use as an ebola vaccine adjuvant. Poly I : C is already years ahead of Ampligen in this regard.
Proc Natl Acad Sci U S A. 2011 Dec 20
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
Some of the prior in vitro and animal studies of interferon-alpha and Ebola:
Antibiot Khimioter. 1995 May;40(5):24-7.
The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections.
J Infect Dis. 1999 Feb;179 Suppl 1:S224-34.
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
There have been in vitro and animal studies using interferon-alpha for Ebola going back to the 1990's.
It would only be news if it turned out that HEB's brand of interferon-alpha did not show an effect in vitro.
"COULD YOU FALL THIS HARD FOR A STOCKBROKER’S SCAM?
A fast-talking broker swindled one doctor out of almost $185,000. Such scenarios happen a lot more often than you’d think.
Clark Gardner was the classic cold-call victim.
Although initially skeptical when a broker he didn’t know phoned, the Los Angeles radiologist was won over by the fellow’s persuasiveness.
...Thirteen months later, the broker had committed almost every cardinal sin in the securities business – among them fraud, churning, and unauthorized trading. And the doctor was out almost $185,000.
Gardner, 52, had fallen into the clutches of a so-called boiler-room operation. Brokers from such outfits hype thinly traded, risky stocks, mostly issued by start-ups with little or no earnings. The brokers buy thousands of shares for pennies each. Then they talk up the stocks to clients, calling the companies “hot,” or “sure winners,” and sell the shares at marked-up prices.
On the strength of the buying, the prices may rise even higher, encouraging the clients to buy more. When the stocks sell out, their prices fall, and investors get stuck. This is known as “pump and dump.”
...Early in November 1994, Gardner took a call from a broker who introduced himself as Samuel Weber of Stratton Oakmont, a Lake Success, NY, firm. Gardner, who already had a broker in Los Angeles, didn’t know the firm.
...About a month later, Weber was on the phone again, recommending that Gardner invest in Hemispherx Bioapharma. This company would become the premier maker of “explosively wonderful” products for treating HIV and other diseases, Weber said. Gardner agreed to invest $11,510. “I’m going to trust you one more time, but don’t ever lead me down a primrose path again,” he said. In fact, the company’s technology was not new, and its effectiveness had been debated for years among pharmaceutical researchers.
les was referring to Adam's post on Twitter, dumdum.
Adam's article on The Street came out later.
Carter & Co do not appear to have any respect for the intelligence of retail investors.
LOL, HEB pumpers have no shame.
Ampligen was a flop in that study and has been dropped.
From HEB's last 10Q:
"In August 2011, a study utilizing Ampligen® was initiated by investigators from the Tumor Vaccine Group (“TVG”) at the University of Washington in Seattle, WA. As of June 30, 2014, 50 patients were enrolled in this ninety-eight patient Phase I-II Study of HER2 vaccination with Ampligen® as an adjuvant in optimally treated breast cancer patients. The goal of this study is to see how well the combination works in treating patients with Stage II-IV human epidermal growth factor receptor 2 (“HER2”)-positive breast cancer. Vaccines made from synthetic HER2/neu peptides may help the body build an effective immune response to kill tumor cells that express HER-2/neu. The TVG has developed vaccines against several cancer proteins, and in this study, they are researching a new approach in an attempt to make the immune response to the vaccine even better. Compounds that specifically stimulate TLR receptors are promising immune stimulators, and Ampligen® has the potential to provide a profile of immune stimulation that could be clinically beneficial. Data from these patients was evaluated and the Company elected to, at this time, to redirect resources to other projects."
The next 10Q should be out in a few weeks. We'll see how many millions of shares HEB dumped in the 3rd quarter soon.
However, his scientific illiteracy does provide abundant amusement in his blustering posts.
Again and again, the adjective that comes to the FDA's lips when describing HEB's data is: "misleading."
There is only the most negligible insider and institutional ownership of HEB.
More than 90% of HEB shares are held by naïve retail investors-- the kind of poor saps who are lured into becoming HEB bagholders by the boiler room operators.